Nijmegen, The Netherlands – January 8, 2009 – Syntarga B.V. announced today
that it has demonstrated strong and broad In Vivo Proof of Concept for Antibody-Drug
Conjugates (ADCs) incorporating the Company's payload technology. The proprietary
platform combines extremely potent duocarmycins, a class of DNA minor groove binding
agents, with linker chemistries that are stable in the circulation and release the cellkilling
agent upon internalization by target-expressing cells.
Systemic administration of different ADCs in human tumor xenograft models with
established tumors, led to strong antitumor efficacy at doses well below the MTD,
ranging from substantial tumor growth inhibition to 100% complete and durable
regressions, with varying study parameters such as dose (including single-digit mg/kg),
dosing route and dosing schedule (including single-dose). Adverse effects were minimal
as indicated by absent or minimal body weight changes in ADC treated groups compared
to naked antibody treated groups. For several linker-duocarmycin chemistries a
significant therapeutic window was demonstrated.
The results indicate the technology's broad applicability against multiple antigen targets
and against a range of cancer indications, including solid tumors. Syntarga has
established itself as a company with ADC technology and technological know-how as to
the structural requirements for a drug-linker to generate successful ADCs.
Syntarga evaluates its payload chemistries through collaborations with contract research
organizations (CROs) and major biopharmaceutical companies. A compilation of in vivo
data will be presented at the forthcoming Protein Engineering Summit (April 6 - 10,
2009, Boston, USA) and at the American Association for Cancer Research Annual Meeting
(April 18 - 22, 2009, Denver, USA).
About Syntarga BV
Syntarga is a private biopharmaceutical company engaged in the discovery and
development of proprietary Antibody-Drug Conjugate technology for the treatment of
cancer. The Company's cutting-edge chemistry capabilities and unique know-how have
led to the creation of Potent Payload Technology, an antibody empowering technology to
generate next generation antibody products for oncology. Syntarga applies its
technologies and expertise to generate and commercialize Antibody-Drug Conjugate
product candidates based on antibodies of its biopharmaceutical partner.
About Potent Payload Technology
Syntarga Potent Payload Technology comprises extremely potent cell-killing agents that
are coupled to suitable linker technologies for attachment to tumor-specific monoclonal
antibodies. The targeting properties of monoclonal antibodies combined with Syntarga’s
unique and fully synthetic Linker-Drug payload chemistries have yielded a variety of ADC
products that have been validated in vivo and were shown to possess a large therapeutic
window. The Company’s preclinical stage technologies are based on its duocarmycins, a
class of DNA-damaging minor groove binding alkylating agents, which possess a range of
unique properties making them highly suitable as ADC warheads.